Download PDF
TumorDiagnostik & Therapie 2023; 44(04): 260-263
DOI: 10.1055/a-1981-0072
Übersicht
Schwerpunkt

Monoklonale Gammopathie unklarer Signifikanz und Smoldering Multiples Myelom

Aileen Schenk
,
Britta Besemer
› Further Information
Also available at
    Permissions and Reprints

Die monoklonale Gammopathie ist ein häufiger laborchemischer Zufallsbefund, der mit steigendem Patientenalter zunimmt. Die Herausforderung liegt darin, diesen Befund richtig einzuordnen hinsichtlich des Vorliegens einer monoklonalen Gammopathie unklarer Signifikanz (MGUS) bzw. klinischer Signifikanz (MGCS) oder des Vorliegens eines (Smoldering) Multiplen Myeloms (SMM) sowie die entsprechenden Verlaufskontrollen festzulegen.

Schlüsselwörter

Monoklonale Gammopathie unklarer Signifikanz (MGUS) - monoklonale Gammopathie klinischer Signifikanz (MGCS) - Smoldering multiples Myelom - SLiM-CRAB


Publication History

Article published online:
29 March 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Ho M, Patel A, Goh CY. et al. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Leukemia 2020; 34: 3111-3125
    CrossrefPubMedSearch in Google Scholar
  • 2 Schieferdecker A, Binder M, Weisel K. et al. Monoklonale Gammopathie unklarer Signifikanz – ein häufiger Nebenbefund. Dtsch Med Wochenschr 2019; 144: 982-989
    Thieme ConnectPubMedSearch in Google Scholar
  • 3 Rajkumar SV, Dimopoulos MA, Palumbo A. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15: e538-e548
    Search in Google Scholar
  • 4 Chaudhry HM, Mauermann ML, Rajkumar SV. Monoclonal Gammopathy-Associated Peripheral Neuropathy: Diagnosis and Management. Mayo Clin Proc 2017; 92: 838-850
    CrossrefPubMedSearch in Google Scholar
  • 5 Kyle RA, Durie BG, Rajkumar SV. et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010; 24: 1121-1127
    Search in Google Scholar
  • 6 de Donk NW, Palumbo A, Johnsen HE. et al. The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. Haematologica 2014; 99: 984-996
    Search in Google Scholar
  • 7 Fermand JP, Bridoux F, Dispenzieri A. et al. Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood 2018; 132: 1478-1485
    CrossrefPubMedSearch in Google Scholar
  • 8 Leung N, Bridoux F, Hutchison CA. et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood 2012; 120: 4292-4295
    CrossrefPubMedSearch in Google Scholar
  • 9 International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-757
    CrossrefPubMedSearch in Google Scholar
  • 10 Dispenzieri A, Stewart AK, Chanan-Khan A. et al. Smoldering multiple myeloma requiring treatment: time for a new definition?. Blood 2013; 122: 4172-4181
    Search in Google Scholar
  • 11 Ravindran A, Bartley AC, Holton SJ. et al. Prevalence, incidence and survival of smoldering multiple myeloma in the United States. Blood Cancer J 2016; 6: e486
    CrossrefPubMedSearch in Google Scholar
  • 12 Kyle RA, Remstein ED, Therneau TM. et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007; 356: 2582-2590
    CrossrefPubMedSearch in Google Scholar
  • 13 Mateos MV, Kumar S, Dimopoulos MA. et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J 2020; 10: 102
    Search in Google Scholar